

# Jessica M Franklin

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6674171/jessica-m-franklin-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

127 papers	3,885 citations	36 h-index	59 g-index
137 ext. papers	5,067 ext. citations	6.7 avg, IF	5.94 L-index

#	Paper	IF	Citations
127	Real-world evidence to support regulatory decision making: New or expanded medical product indications. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2021</b> , 30, 685-693	2.6	6
126	How well can we assess the validity of non-randomised studies of medications? A systematic review of assessment tools. <i>BMJ Open</i> , <b>2021</b> , 11, e043961	3	4
125	Prescription opioid use after vaginal delivery and subsequent persistent opioid use and misuse. <i>American Journal of Obstetrics &amp; Gynecology MFM</i> , <b>2021</b> , 3, 100304	7.4	2
124	When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> ,	6.1	5
123	Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. <i>Circulation</i> , <b>2021</b> , 143, 1002-1013	16.7	52
122	Postoperative inpatient utilization of opioid and opioid-sparing analgesics in the United States hospitals, 2007-2017. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2021</b> , 30, 390-394	2.6	4
121	A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer. <i>EClinicalMedicine</i> , <b>2021</b> , 32, 100730	11.3	4
120	Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA. <i>Journal of General Internal Medicine</i> , <b>2021</b> , 36, 2601-2607	4	0
119	Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 109, 816-828	6.1	3
118	Response by Franklin and Schneeweiss to Letters Regarding Article, "Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative". <i>Circulation</i> , <b>2021</b> , 144, e162-e163	16.7	2
117	Prevalence, predictors, and outcomes of both true- and pseudo-resistant hypertension in the action to control cardiovascular risk in diabetes trial: a cohort study. <i>Hypertension Research</i> , <b>2021</b> , 44, 1471-1482	4.7	3
116	Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29, 1228-1235	2.6	24
115	Emulation Differences vs. Biases When Calibrating Real-World Evidence Findings Against Randomized Controlled Trials. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 735-737	6.1	9
114	Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 874-884	6.1	1
113	Predicting overdose among individuals prescribed opioids using routinely collected healthcare utilization data. <i>PLoS ONE</i> , <b>2020</b> , 15, e0241083	3.7	5
112	Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 18, 36-43	7.3	11
111	Use of Time-Dependent Propensity Scores to Adjust Hazard Ratio Estimates in Cohort Studies with Differential Depletion of Susceptibles. <i>Epidemiology</i> , <b>2020</b> , 31, 82-89	3.1	5

110	The EMPagliflozin compaRative effectiveness and SaFety (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care. <i>Endocrinology, Diabetes and Metabolism</i> , <b>2020</b> , 3, e00103	2.7	3
109	Comparative Outcomes of Treatment Initiation With Brand vs. Generic Warfarin in Older Patients. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 1334-1342	6.1	1
108	Evaluating the Utility of Coarsened Exact Matching for Pharmacoepidemiology Using Real and Simulated Claims Data. <i>American Journal of Epidemiology</i> , <b>2020</b> , 189, 613-622	3.8	13
107	Consequences of Depletion of Susceptibles for Hazard Ratio Estimators Based on Propensity Scores. <i>Epidemiology</i> , <b>2020</b> , 31, 806-814	3.1	3
106	Brief discussion on sampling variability in 1:1 propensity score matching without replacement. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29, 1194-1197	2.6	
105	Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 817-826	6.1	31
104	Association of Gabapentinoids With the Risk of Opioid-Related Adverse Events in Surgical Patients in the United States. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2031647	10.4	24
103	Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 1513-1521	6.1	10
102	Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2029-2038	6.7	11
101	Evaluating the use of bootstrapping in cohort studies conducted with 1:1 propensity score matching-A plasmode simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 879-886	2.6	2
100	Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. <i>Circulation</i> , <b>2019</b> , 139, 2822-2830	16.7	116
99	Propensity score prediction for electronic healthcare databases using Super Learner and High-dimensional Propensity Score Methods. <i>Journal of Applied Statistics</i> , <b>2019</b> , 46, 2216-2236	1	12
98	Sequential Monitoring of the Comparative Effectiveness and Safety of Dabigatran in Routine Care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2019</b> , 12, e005173	5.8	7
97	Impact of State Laws Restricting Opioid Duration on Characteristics of New Opioid Prescriptions. <i>Journal of General Internal Medicine</i> , <b>2019</b> , 34, 2339-2341	4	13
96	A concept-wide association study to identify potential risk factors for nonadherence among prevalent users of antihypertensives. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 1299-1308	2.6	1
95	Public Approval of Exception From Informed Consent in Emergency Clinical Trials: A Systematic Review of Community Consultation Surveys. <i>JAMA Network Open</i> , <b>2019</b> , 2, e197591	10.4	9
94	Association of Preoperative Opioid Use With Mortality and Short-term Safety Outcomes After Total Knee Replacement. <i>JAMA Network Open</i> , <b>2019</b> , 2, e198061	10.4	32
93	Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride. <i>Diabetes Care</i> , <b>2019</b> , 42, 2204-2210	14.6	50

92	Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. <i>BMJ, The</i> , <b>2019</b> , 367, l5657	5.9	119
91	Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 867-877	6.1	68
90	Claims Data Studies of Direct Oral Anticoagulants Can Achieve Balance in Important Clinical Parameters Only Observable in Electronic Health Records. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 979-993	6.1	10
89	Multinomial Extension of Propensity Score Trimming Methods: A Simulation Study. <i>American Journal of Epidemiology</i> , <b>2019</b> , 188, 609-616	3.8	11
88	Scalable collaborative targeted learning for high-dimensional data. <i>Statistical Methods in Medical Research</i> , <b>2019</b> , 28, 532-554	2.3	15
87	Collaborative-controlled LASSO for constructing propensity score-based estimators in high-dimensional data. <i>Statistical Methods in Medical Research</i> , <b>2019</b> , 28, 1044-1063	2.3	15
86	Application and impact of run-in studies. <i>Journal of General Internal Medicine</i> , <b>2018</b> , 33, 759-763	4	16
85	Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 383-390	2.6	1
84	Application and Impact of Run-In Studies for the Evaluation of Statin Efficacy and Safety. <i>Journal of General Internal Medicine</i> , <b>2018</b> , 33, 792-794	4	3
83	Using Super Learner Prediction Modeling to Improve High-dimensional Propensity Score Estimation. <i>Epidemiology</i> , <b>2018</b> , 29, 96-106	3.1	38
82	Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis. <i>JAMA Network Open</i> , <b>2018</b> , 1, e180826	10.4	40
81	Predicting Adherence to Chronic Disease Medications in Patients with Long-term Initial Medication Fills Using Indicators of Clinical Events and Health Behaviors. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2018</b> , 24, 469-477	1.9	24
80	Changes in Outpatient Use of Antibiotics by Adults in the United States, 2006-2015. <i>Drug Safety</i> , <b>2018</b> , 41, 1333-1342	5.1	11
79	Implications of the Propensity Score Matching Paradox in Pharmacoepidemiology. <i>American Journal of Epidemiology</i> , <b>2018</b> , 187, 1951-1961	3.8	24
78	An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout. <i>PLoS ONE</i> , <b>2018</b> , 13, e0193622	3.7	21
77	The relative benefits of claims and electronic health record data for predicting medication adherence trajectory. <i>American Heart Journal</i> , <b>2018</b> , 197, 153-162	4.9	13
76	Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 974-984	6.7	46
75	Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1805-1812	2.2	41

74	Impact of High Deductible Health Plans on Cardiovascular Medication Adherence and Health Disparities. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2018</b> , 11, e004632	5.8	17
73	Time to Filling of New Prescriptions for Chronic Disease Medications Among a Cohort of Elderly Patients in the USA. <i>Journal of General Internal Medicine</i> , <b>2018</b> , 33, 1877-1884	4	7
72	Effect of Reminder Devices on Medication Adherence: The REMIND Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , <b>2017</b> , 177, 624-631	11.5	103
71	Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 694-701	2.6	4
70	Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2017</b> , 10,	5.8	4
69	Patient-Centered Medical Homes and Adherence to Chronic Disease Medications. <i>Annals of Internal Medicine</i> , <b>2017</b> , 166, 761-762	8	
68	Effects of expanding the look-back period to all available data in the assessment of covariates. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 890-899	2.6	24
67	Variable Selection for Confounding Adjustment in High-dimensional Covariate Spaces When Analyzing Healthcare Databases. <i>Epidemiology</i> , <b>2017</b> , 28, 237-248	3.1	36
66	Matching Weights to Simultaneously Compare Three Treatment Groups: Comparison to Three-way Matching. <i>Epidemiology</i> , <b>2017</b> , 28, 387-395	3.1	64
65	Variation in adherence to medications across the healthcare system in two comparative effectiveness research cohorts. <i>Journal of Comparative Effectiveness Research</i> , <b>2017</b> , 6, 613-625	2.1	2
64	The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine. <i>PLoS ONE</i> , <b>2017</b> , 12, e0175313	3.7	1
63	When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 924-933	6.1	119
62	Association of the Priority Review Voucher With Neglected Tropical Disease Drug and Vaccine Development. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 388-389	27.4	11
61	Longitudinal Patterns of Spending Enhance the Ability to Predict Costly Patients: A Novel Approach to Identify Patients for Cost Containment. <i>Medical Care</i> , <b>2017</b> , 55, 64-73	3.1	13
60	Alendronate and Hip Fracture in Patients Using Glucocorticoids. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 1711-1712	27.4	
59	Assessment of Confounders in Comparative Effectiveness Studies From Secondary Databases. <i>American Journal of Epidemiology</i> , <b>2017</b> , 185, 474-478	3.8	5
58	Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 130	5.7	2
57	A Bias in the Evaluation of Bias Comparing Randomized Trials with Nonexperimental Studies. <i>Epidemiologic Methods</i> , <b>2017</b> , 6,	2.2	11

56	Association Between Patient-Centered Medical Homes and Adherence to Chronic Disease Medications: A Cohort Study. <i>Annals of Internal Medicine</i> , <b>2017</b> , 166, 81-88	8	30
55	The international generalisability of evidence for health policy: A cross country comparison of medication adherence following policy change. <i>Health Policy</i> , <b>2017</b> , 121, 27-34	3.2	4
54	Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 387-397	9.5	46
53	Predicting 1-Year Statin Adherence Among Prevalent Users: A Retrospective Cohort Study. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2017</b> , 23, 494-502	1.9	16
52	Comparing the performance of propensity score methods in healthcare database studies with rare outcomes. <i>Statistics in Medicine</i> , <b>2017</b> , 36, 1946-1963	2.3	49
51	Response to the Comment on Evaluating Cardiovascular Health Disparities Using Estimated Race/Ethnicity: A Validation Study. <i>Medical Care</i> , <b>2016</b> , 54, 965-6	3.1	
50	Impact of the U.S. Food and Drug Administration's Safety-Related Announcements on the Use of Bisphosphonates After Hip Fracture. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 1536-40	6.3	76
49	Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey. <i>Journal of General Internal Medicine</i> , <b>2016</b> , 31, 609-14	4	40
48	Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval. <i>PLoS ONE</i> , <b>2016</b> , 11, e0163339	3.7	7
47	Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0152195	3.7	2
46	Comparative validity of methods to select appropriate cutoff weight for probabilistic linkage without unique personal identifiers. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25, 444-52	2.6	5
45	Can purchasing information be used to predict adherence to cardiovascular medications? An analysis of linked retail pharmacy and insurance claims data. <i>BMJ Open</i> , <b>2016</b> , 6, e011015	3	3
44	Persistent opioid use following cesarean delivery: patterns and predictors among opioid-naïve women. <i>American Journal of Obstetrics and Gynecology</i> , <b>2016</b> , 215, 353.e1-353.e18	6.4	153
43	Physicians' Knowledge About FDA Approval Standards and Perceptions of the "Breakthrough Therapy" Designation. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 1516-8	27.4	35
42	Prevalence and Predictors of Generic Drug Skepticism Among Physicians: Results of a National Survey. <i>JAMA Internal Medicine</i> , <b>2016</b> , 176, 845-7	11.5	37
41	Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts. <i>JAMA Internal Medicine</i> , <b>2016</b> , 176, 763-8	11.5	131
40	P-values and decision-making: discussion of Limitations of empirical calibration of p-values using observational data. <i>Statistics in Medicine</i> , <b>2016</b> , 35, 3889-91	2.3	2
39	Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012. <i>JACC Basic To Translational Science</i> , <b>2016</b> , 1, 301-308	8.7	14



38	Payments to Physicians, Prescribing Rates, and More Appropriate Conclusions-Reply. <i>JAMA Internal Medicine</i> , <b>2016</b> , 176, 1577	11.5	
37	Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. <i>JAMA Internal Medicine</i> , <b>2016</b> , 176, 1826-1833	11.5	177
36	Observing versus Predicting: Initial Patterns of Filling Predict Long-Term Adherence More Accurately Than High-Dimensional Modeling Techniques. <i>Health Services Research</i> , <b>2016</b> , 51, 220-39	3.4	43
35	Regularized Regression Versus the High-Dimensional Propensity Score for Confounding Adjustment in Secondary Database Analyses. <i>American Journal of Epidemiology</i> , <b>2015</b> , 182, 651-9	3.8	33
34	Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. <i>American Journal of Medicine</i> , <b>2015</b> , 128, 539.e7-17	2.4	21
33	Surgeon case volume and 30-day mortality after carotid endarterectomy among contemporary medicare beneficiaries: before and after national coverage determination for carotid artery stenting. <i>Stroke</i> , <b>2015</b> , 46, 1288-94	6.7	35
32	Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. <i>Journal of General Internal Medicine</i> , <b>2015</b> , 30, 1633-8	4	11
31	Statins and congenital malformations: cohort study. <i>BMJ, The</i> , <b>2015</b> , 350, h1035	5.9	126
30	Incorporating linked healthcare claims to improve confounding control in a study of in-hospital medication use. <i>Drug Safety</i> , <b>2015</b> , 38, 589-600	5.1	5
29	Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 1577-85	9.5	123
28	Antipsychotics and mortality: adjusting for mortality risk scores to address confounding by terminal illness. <i>Journal of the American Geriatrics Society</i> , <b>2015</b> , 63, 516-23	5.6	15
27	Selective Serotonin Reuptake Inhibitor Use and Perioperative Bleeding and Mortality in Patients Undergoing Coronary Artery Bypass Grafting: A Cohort Study. <i>Drug Safety</i> , <b>2015</b> , 38, 1075-82	5.1	7
26	Two decades of new drug development for central nervous system disorders. <i>Nature Reviews Drug Discovery</i> , <b>2015</b> , 14, 815-6	64.1	75
25	Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study. <i>American Journal of Obstetrics and Gynecology</i> , <b>2015</b> , 212, 337.e1-14	6.4	40
24	Association between trajectories of statin adherence and subsequent cardiovascular events. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2015</b> , 24, 1105-13	2.6	51
23	Evaluating Cardiovascular Health Disparities Using Estimated Race/Ethnicity: A Validation Study. <i>Medical Care</i> , <b>2015</b> , 53, 1050-7	3.1	5
22	Medical Schools Industry Interaction Policies Not Associated With Trainees Self-Reported Behavior as Residents: Results of a National Survey. <i>Journal of Graduate Medical Education</i> , <b>2015</b> , 7, 595-602	16	9
21	Rationale and design of the Randomized Evaluation to Measure Improvements in Non-adherence from Low-Cost Devices (REMIND) trial. <i>Contemporary Clinical Trials</i> , <b>2015</b> , 43, 53-9	2.3	6

20	Predicting adherence trajectory using initial patterns of medication filling. <i>American Journal of Managed Care</i> , <b>2015</b> , 21, e537-44	2.1	24
19	Patterns of treatment among a cohort of older low-income adults starting new medications for osteoporosis. <i>Osteoporosis International</i> , <b>2014</b> , 25, 2255-62	5.3	1
18	Plasmode simulation for the evaluation of pharmacoepidemiologic methods in complex healthcare databases. <i>Computational Statistics and Data Analysis</i> , <b>2014</b> , 72, 219-226	1.6	60
17	Antidepressant use in pregnancy and the risk of cardiac defects. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 2397-407	59.2	222
16	Prospective cohort studies of newly marketed medications: using covariate data to inform the design of large-scale studies. <i>Epidemiology</i> , <b>2014</b> , 25, 126-33	3.1	14
15	Association of medical students' reports of interactions with the pharmaceutical and medical device industries and medical school policies and characteristics: a cross-sectional study. <i>PLoS Medicine</i> , <b>2014</b> , 11, e1001743	11.6	9
14	Instrumental variable applications using nursing home prescribing preferences in comparative effectiveness research. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2014</b> , 23, 830-8	2.6	6
13	Metrics for covariate balance in cohort studies of causal effects. <i>Statistics in Medicine</i> , <b>2014</b> , 33, 1685-99	2.3	145
12	Association of marketing interactions with medical trainees' knowledge about evidence-based prescribing: results from a national survey. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 1283-90	11.5	29
11	Changing interactions between physician trainees and the pharmaceutical industry: a national survey. <i>Journal of General Internal Medicine</i> , <b>2013</b> , 28, 1064-71	4	49
10	Physician trainees' interactions with the pharmaceutical industry. <i>Journal of General Internal Medicine</i> , <b>2013</b> , 28, 1267	4	2
9	Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 2008-14	4.7	21
8	Adjuvant vancomycin for antibiotic prophylaxis and risk of <i>Clostridium difficile</i> infection after coronary artery bypass graft surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2013</b> , 146, 472-8	1.5	10
7	Distributions of industry payments to Massachusetts physicians. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 2049-52	59.2	46
6	The risk of congenital malformations associated with exposure to $\beta$ -blockers early in pregnancy: a meta-analysis. <i>Hypertension</i> , <b>2013</b> , 62, 375-81	8.5	78
5	Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. <i>BMJ</i> , <b>2013</b> , 347, f5416	5.9	52
4	Sequential value-of-information assessment for prospective drug safety monitoring using claims databases: the comparative safety of prasugrel v. clopidogrel. <i>Medical Decision Making</i> , <b>2013</b> , 33, 949-60	2.5	4
3	Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs. <i>BMJ Quality and Safety</i> , <b>2013</b> , 22, 727-34	5.4	25



2	Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. <i>Medical Care</i> , <b>2013</b> , 51, 789-96	3.1	133
1	Matching by propensity score in cohort studies with three treatment groups. <i>Epidemiology</i> , <b>2013</b> , 24, 401-9	3.1	103